BCVPP Chemotherapy for Advanced Hodgkin's Disease: Evidence for Greater Duration of Complete Remission, Greater Survival, and Less Toxicity Than with a MOPP Regimen

Abstract

Two chemotherapy regimens for treatment of patients with advanced Hodgkin''s disease, BCVPP (carmustine, cyclophosphamide, vinblastine, procarbazine, and prednisone) and MOPP (mechlorethamine hydrochloride, vincristine, procarbazine, and prednisone), were compared in a randomized prospective study. Patients (293) were evaluable in the induction phase of this study. The complete remission rate with BCVPP was 76% (112/147) and with MOPP, 73% (106/146) (P = 0.51). The duration of complete remissions for previously untreated patients given BCVPP was significantly longer than that for previously untreated patients given MOPP (P = 0.02). Although hematologic toxicities were similar, BCVPP caused less gastrointestinal (P = 0.0001) and neurologic toxicity (P = 0.01) than MOPP. Previously untreated patients achieving complete remission with BCVPP survived significantly longer than those receiving MOPP (P = 0.03). As primary induction chemotherapy for advanced Hodgkin''s disease, BCVPP is an effective alternative to MOPP, having equal or greater therapeutic benefit with less toxicity.